Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson’s disease

  • Th. Müller
  • S. Benz
  • Ch. Börnke
  • S. Muhlack
  • D. Woitalla
  • H. Przuntek
Chapter
Part of the Journal of Neural Transmission. Supplementa book series (NEURAL SUPPL, volume 68)

Summary

Instrumental tests and clinical rating assess motor disability in Parkinson’s disease (PD) patients. Previous long-term dopaminergic substitution influences the behaviour following acute dopaminergic stimulation. Objective of this study was to investigate the motor response following an apomorphine application in previously untreated-, treated- and before treated PD patients , who received placebo. Outcomes of instrumental tests worsened in previously untreated-, but not in before treated PD patients after apomorphine injection and in the PD subjects under the placebo condition . Generally, rating scores of motor symptoms significantly improved after apomorphine administration, whereas placebo application showed no effects. Tolerance to sedative effects of apomorphine in treated PD patients or sensitivity of employed motor tests to presynaptic dopaminergic autoreceptor mediated inhibition of endogenous dopamine release or postsynaptic dopaminergic overstimulation with resulting decreased cognitive function in previously untreated PD patients hypothetically caused this discrepancy between outcomes of subjective clinical rating and objective motor test performance.

Keywords

Motor Test Motor Test Performance Apomorphine Injection Apomorphine Dose Endogenous Dopamine Release 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Andreu N, Chale JJ, Senard JM, Thalamas C, Montastruc JL, Rascol O (1999) L-Dopa-induced sedation: a double-blind cross-over controlled study versus triazolam and placebo in healthy volunteers. Clin Neurophannacol 22: 15–23CrossRefGoogle Scholar
  2. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL (1997) Long-term changes of striatal dopam ine D2 receptors in patient s with Parkinson’s disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 12: 33–38PubMedCrossRefGoogle Scholar
  3. Ekesbo A, Rydin E, Torstenson R, Sydow O, Laengstrom B, Tedroff J (1999) Dopamine autoreceptor function is lost in advanced Parkinson’s disease. Neurology 52: 120–125PubMedCrossRefGoogle Scholar
  4. Friedman JI, Temporini H, Davis KL (1999) Pharmacologic strategies for augmenting cognitive performance in schizophrenia. BioI Psychiatry 45: 1–16CrossRefGoogle Scholar
  5. Fuente-Fernandez R, Lim AS, Sossi V, Holden JE, Calne DB, Ruth TJ, Stoessl AJ (2001a) Apomorphine-induced changes in synaptic dopamine levels: positron emission tomography evidence for presynaptic inhibition. J Cereb Blood Flow Metab 21: 1151–1159CrossRefGoogle Scholar
  6. Fuente-Fernandez R, Ruth TJ, Sossi V, Schulzer M, Calne DB, Stoessl AJ (2001b) Expectation and dopamine release: mechanism of the placebo effect in Parkinson’s disease. Science 293: 1164–1166PubMedCrossRefGoogle Scholar
  7. Fuente-Fernandez R, Phillips AG, Zamburlini M, Sossi V, Calne DB, Ruth TJ, Stoessl AJ (2002) Dopamine release in human ventral striatum and expectation of reward. Behav Brain Res 136: 359–363PubMedCrossRefGoogle Scholar
  8. Gordon AM, Reilmann R (1999) Getting a grasp on research: does treatment taint testing of parkinsoni an patients? [letter]. Brain 122(Pt 8): 1597–1598PubMedCrossRefGoogle Scholar
  9. Goren JL, Friedman JH (1998) Yawning as an aura for an L-dopa-induced “on” in Parkinson’s disease [see comments]. Neurology 50: 823PubMedCrossRefGoogle Scholar
  10. Grandas F, Obeso JA (1989) Motor response following repeated apomorphine administration is reduced in Parkinson’s disease. Clin Neuropharmacol 12: 14–22PubMedCrossRefGoogle Scholar
  11. Grandas F, Gancher ST, Rodriguez M, Lera G, Nutt JG, Obeso JA (1992) Differences in the motor response to apomorphine between untreated and fluctuating patients with Parkinson’s disease. Clin Neuropharmacol 15: 13–18PubMedCrossRefGoogle Scholar
  12. Hughes AJ, Lees AJ, Stern GM (1991) Challenge tests to predict the dopaminergic response in untreated Parkinson’s disease. Neurology 41: 1723–1725PubMedCrossRefGoogle Scholar
  13. Iversen SD (1998) The pharmacology of memory. CR Acad Sci III 321: 209–215CrossRefGoogle Scholar
  14. Kulisevsky J, AvilaA, Barbanoj M, Antonijoan R, Berthier ML, Gironell A (1996) Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson’s disease patients at different levodopa plasma levels. Brain 119 (Pt 6): 2121–2132PubMedCrossRefGoogle Scholar
  15. Montastruc JL, Llau ME, Senard JM, Tran MA, Rascol O, Montastruc P (1996) A study of tolerance to apomorphine. Br J Pharmacol 117: 781–786PubMedCrossRefGoogle Scholar
  16. Müller T, Eising EG, Reiners C, Przuntek H, Jacob M, Kuhn W (1997) 2-[123I]-iodolisuride SPET visualizes dopaminergic loss in de-novo parkinsonian patients: is it a marker of striatal pre-synaptic degeneration? Nucl Med Commun 18: 1115–1121PubMedCrossRefGoogle Scholar
  17. Müller T, Benz S, Przuntek H (2000a) Choice reaction time after levodopa challenge in parkinsonian patients. J Neurol Sci 181: 98–103PubMedCrossRefGoogle Scholar
  18. Müller T, Schafer S, Kuhn W, Przuntek H (2000b) Correlation between tapping and inserting of pegs in Parkinson’s disease. Can J Neurol Sci 27: 311–315PubMedGoogle Scholar
  19. Müller T, Woitalla D, Saft C, Kuhn W (2000c) Levodopa in plasma correlates with body weight of parkinsonian patients. Parkinsonism ReI Disord 6: 171–173CrossRefGoogle Scholar
  20. Müller T, Benz S, Przuntek H (2002b) Tapping and peg insertion after levodopa intake in treated and de novo parkinsonian patients. Can J Neurol Sci 29: 73–77PubMedGoogle Scholar
  21. Müller T, Benz S, Bornke C, Russ H, Przuntek H (2003a) Repeated rating improves value of diagnostic dopaminergic challenge tests in Parkinson’s disease. J Neural Transm 110: 603–609PubMedCrossRefGoogle Scholar
  22. Müller T, Kuhn W, Schulte T, Przuntek H (2003b) Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson’s disease. Neurosci Lett 339: 25–28PubMedCrossRefGoogle Scholar
  23. Nutt JG, Lea ES, Van Houten L, Schuff RA, Sexton GJ (2000) Determinants of tapping speed in normal control subjects and subjects with Parkinson’s disease: differing effects of brief and continued practice. Mov Disord 15: 843–849PubMedCrossRefGoogle Scholar
  24. Piccini P, Pavese N, Brooks DJ (2003) Endogenous dopamine release after pharmacological challenges in Parkinson’s disease. Ann Neurol 53: 647–653PubMedCrossRefGoogle Scholar
  25. Rioux L, Frohna PA, Joyce IN, Schneider JS (1997) The effects of chronic levodopa treatment on pre-and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys. Mov Disord 12: 148–158PubMedCrossRefGoogle Scholar
  26. Ruzicka E, Roth J, Spackova N, Mecir P, Jech R (1994) Apomorphine induced cognitive changes in Parkinson’s disease. J Neurol Neurosurg Psychiatry 57: 998–1001PubMedCrossRefGoogle Scholar
  27. Skirboll LR, Grace AA, Bunney BS (1979) Dopamine auto-and postsynaptic receptors: electrophysiological evidence for differential sensitivity to dopamine agonists. Science 206: 80–82PubMedCrossRefGoogle Scholar
  28. Strafella AP, Valzania F, Nasetti SA, Tropeani A, Bisulli A, Santangelo M, Tassinari CA (2000) Effects of chronic levodopa and pergolide treatment on cortical excitability in patients with Parkinson’s disease: a transcranial magnetic stimulation study. Clin Neurophysiol 111: 1198–1202PubMedCrossRefGoogle Scholar
  29. Yang CR, Mogenson GJ (1990) Dopaminergic modulation of cholinergic responses in rat medial prefrontal cortex: an electrophysiological study. Brain Res 524: 271–281PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2004

Authors and Affiliations

  • Th. Müller
    • 1
  • S. Benz
    • 1
  • Ch. Börnke
    • 1
  • S. Muhlack
    • 1
  • D. Woitalla
    • 1
  • H. Przuntek
    • 1
  1. 1.Department of Neurology, St. Josef HospitalRuhr University BochumBochumGermany

Personalised recommendations